“Sonoma reported F2Q19 (March in total revenues up 13% sequentially, and a net loss of ($2.8M). US product revenues were $2.4M, an increase of 23% from F1Q19. Ex-US revenues also increased to $2.2M, from $2.1M (4% sequential growth) in F1Q19. The company ended the period with $4M in cash, or just over a quarter of operating capital. Conclusion: Sonoma reported modest growth in the quarter and we note that product sales are at record levels, a positive for the company. We are watching for the launch of products in Brazil through partner U.SK (Private), and uptake in the mail order program. Our concern has been the capital needs of the company which Sonoma is currently working to address. We remain Hold rated.”,” Maxim Group’s analyst wrote.
A number of other equities analysts have also weighed in on the stock. ValuEngine upgraded shares of Sonoma Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, September 12th. Zacks Investment Research lowered shares of Sonoma Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, August 29th. Finally, Benchmark restated a speculative buy rating and set a $3.00 price target on shares of Sonoma Pharmaceuticals in a research report on Friday, July 20th.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its quarterly earnings results on Thursday, November 8th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.02. The firm had revenue of $4.94 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 83.05% and a negative return on equity of 97.88%. On average, analysts expect that Sonoma Pharmaceuticals will post -2 earnings per share for the current year.
An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Renaissance Technologies LLC increased its holdings in shares of Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) by 54.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 91,095 shares of the company’s stock after acquiring an additional 32,180 shares during the quarter. Renaissance Technologies LLC owned about 1.41% of Sonoma Pharmaceuticals worth $226,000 at the end of the most recent reporting period. 11.32% of the stock is owned by hedge funds and other institutional investors.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions.
Recommended Story: Relative Strength Index
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.